(NASDAQ: BCRX) Biocryst Pharmaceuticals's forecast annual revenue growth rate of 7.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.83%.
Biocryst Pharmaceuticals's revenue in 2025 is $599,816,000.On average, 13 Wall Street analysts forecast BCRX's revenue for 2025 to be $132,835,930,886, with the lowest BCRX revenue forecast at $126,502,790,708, and the highest BCRX revenue forecast at $138,017,399,629. On average, 13 Wall Street analysts forecast BCRX's revenue for 2026 to be $142,291,427,076, with the lowest BCRX revenue forecast at $129,164,057,060, and the highest BCRX revenue forecast at $151,433,213,862.
In 2027, BCRX is forecast to generate $155,943,049,720 in revenue, with the lowest revenue forecast at $136,592,022,002 and the highest revenue forecast at $169,516,771,371.